Exelixis gets a bullish signal as it hit the lower rail of an upward sloped channel
Biotech firm Exelixis (Nasdaq: EXEL) has been trending sharply higher since the end of October and a trend channel has formed that defines the up and down cycles within the overall upward trend. The lower rail of the channel is formed by the lows in October and December while the upper rail is formed by the highs in December and January. The stock has been grinding sideways with a slight downward bias since mid-January and that has allowed the lower rail of the channel to catch up to the stock price.
With the stock hitting the lower rail it looks as if the next upward cycle is underway. We see that the daily stochastic readings made a bullish crossover on February 25 as the stock moved back above its 50-day moving average.
The upward cycle that started in October and ended in early December saw the stock gain over 65% from the high to the low. The upward cycle that started in late December and ran through mid-January saw the stock gain over 40%. Expecting another move like that might be asking too much, but it isn’t out of the question.
The Tickeron AI Prediction tool generated a bullish signal on Exelixis on February 22. That prediction came with a 75% confidence level for a move of at least 4% to the upside. Previous predictions of this nature have been successful 84% of the time.
The company’s fundamentals are really good as earnings and sales have grown tremendously in recent years. Earnings have grown by an average of 503% per year over the last three years while sales have averaged annual growth of 193% over that same period.
Exelixis sports a return on equity of 56.7% and a profit margin of 35%. The company has no long-term debt.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
EXEL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EXEL turned positive on August 20, 2026. Looking at past instances where EXEL's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 20, 2026. You may want to consider a long position or call options on EXEL as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EXEL advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .
EXEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
EXEL moved below its 50-day moving average on August 20, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EXEL crossed bearishly below the 50-day moving average on August 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXEL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for EXEL entered a downward trend on August 14, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EXEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.267) is normal, around the industry mean (20.143). P/E Ratio (17.006) is within average values for comparable stocks, (22.992). Projected Growth (PEG Ratio) (2.618) is also within normal values, averaging (3.861). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (6.006) is also within normal values, averaging (444.692).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of small molecule therapies for the treatment of cancer
Industry Biotechnology
Advertisement